Hydracort

Hydracort is a prescription medication whose active ingredient is hydrocortisone, a synthetic glucocorticoid. It is supplied in oral dosage form, although specific strength and formulation details are not disclosed. As a corticosteroid, Hydracort is used to replace deficient cortisol and to manage inflammatory or immune‑mediated conditions. The product is marketed within the European Union and requires a physician’s prescription. It is generally prescribed for adults.

Hydracort (hydrocortisone) is indicated for several medical conditions that require glucocorticoid therapy.

- Replacement therapy for primary or secondary adrenal insufficiency (e.g., Addison’s disease). - Management of acute inflammatory episodes in autoimmune disorders such as rheumatoid arthritis or systemic lupus erythematosus. - Treatment of severe allergic reactions, including anaphylaxis, when oral therapy is appropriate. - Adjunctive therapy for certain endocrine disorders requiring cortisol supplementation. - Short‑term control of inflammation in dermatologic or gastrointestinal conditions when oral administration is preferred.

Oral hydrocortisone can cause a range of adverse reactions, which vary in frequency and severity.

Common: - Mild gastrointestinal discomfort, such as nausea or dyspepsia. - Transient increase in blood glucose levels, especially in patients with diabetes. - Fluid retention leading to mild peripheral edema. - Mood changes including irritability or mild insomnia. - Skin thinning or easy bruising.

Serious: - Significant hyperglycemia or new‑onset diabetes mellitus. - Severe electrolyte disturbances, such as hypokalemia or hypertension. - Opportunistic infections due to immunosuppression. - Adrenal crisis on abrupt discontinuation after prolonged therapy. - Severe psychiatric effects such as psychosis or depression.

Before initiating Hydracort, clinicians should evaluate several safety considerations to minimize risk.

- Assess for active infections, as glucocorticoids can worsen bacterial, viral, or fungal diseases. - Screen for uncontrolled diabetes or hypertension, which may be exacerbated by therapy. - Evaluate for a history of peptic ulcer disease or gastrointestinal bleeding. - Use the lowest effective dose for the shortest duration necessary to reduce adverse effects. - Monitor electrolyte balance, especially potassium and sodium levels, during prolonged treatment. - Counsel patients on the need for gradual tapering to avoid adrenal insufficiency after long‑term use.

Hydrocortisone may interact with other medicines, altering its effectiveness or increasing toxicity.

Avoid: - Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that can reduce hydrocortisone levels. - Combining with other systemic corticosteroids, which may amplify immunosuppressive and metabolic effects.

Use with caution: - Anticoagulants such as warfarin, where glucocorticoids can affect INR. - Non‑steroidal anti‑inflammatory drugs (NSAIDs), increasing the risk of gastrointestinal ulceration. - Vaccines, particularly live attenuated vaccines, due to possible reduced immune response. - Diabetic agents, as hydrocortisone may raise blood glucose and require dose adjustment. - Antihypertensive medications, especially ACE inhibitors, may have altered efficacy.